Physician profile
Daniel Kim
NPI 1275813370
$7,616.98
in general payments reported to CMS, 2019-2025
28 companies · $914 in 2025
The $914 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $218 · 2022: $3,349 · 2023: $2,321 · 2024: $815 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,048 · Travel and Lodging: $2.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,047.98 |
| Travel and Lodging | $2.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $2,867.06 | 2022-2023 | Ilumya, Winlevi, Absorica Ld |
| Abbvie INC. | $839.38 | 2022-2025 | |
| Lilly USA, LLC | $750.15 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $428.82 | 2023-2025 | Sotyktu |
| Genzyme Corporation | $426.88 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $342.99 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $314.52 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $294.01 | 2022-2025 | Dupixent |
| Amgen INC. | $262.59 | 2023 | Otezla |
| Pfizer INC. | $185.62 | 2023 | |
| Prugen, INC. Pharmaceuticals | $175.00 | 2021 | |
| Incyte Corporation | $133.20 | 2023-2025 | Opzelura |
| Leo Pharma INC. | $125.00 | 2023 | Adbry |
| Janssen Biotech, INC. | $119.76 | 2023 | Tremfya, Simponi, Remicade |
| Organon LLC | $57.08 | 2025 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $42.83 | 2023-2024 | Spravato |
| Ucb, INC. | $27.78 | 2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $26.35 | 2021 | |
| Eisai INC. | $23.85 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.37 | 2023 | Spevigo |
| Alexion Pharmaceuticals, INC. | $22.32 | 2022 | |
| Dermavant Sciences, INC. | $21.79 | 2023 | Vtama |
| Strata Skin Sciences, INC. | $20.75 | 2025 | Xtrac |
| Epi Health, LLC | $19.59 | 2022 | |
| Arbor Pharmaceuticals, INC. | $19.31 | 2022 | |
| Axsome Therapeutics, INC. | $17.18 | 2024 | Auvelity |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.85 | 2022 | |
| Tolmar, INC. | $13.95 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.